Poor Outcome After LVAD with this poor outcome after LVAD. Our hope was that these data could provide patients and their families with more realistic expectations of recovery and could facilitate shared medical decision making.
Methods

Study Population and Protocol
Our study cohort was derived from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-a multicenter, observational registry of patients receiving mechanical circulatory support in the United States. 7 INTERMACS is administered through a contract from the National Heart, Lung, and Blood Institute to the University of Alabama at Birmingham and is focused on quality improvement and scientific research. All consecutive, nonincarcerated, adult patients who receive Food and Drug Administration-approved devices are screened for enrollment in the registry. At the time of device implant, the surgeon indicates the indication for LVAD, with multiple options including destination therapy (ie, not eligible for heart transplant) and bridge to transplant, with further qualification that includes transplant unlikely/moderate/ likely/listed. For this analysis, we excluded patients who received total artificial hearts, right ventricular and biventricular assist devices, and LVADs for indication other than destination therapy or bridge to transplant-transplant unlikely. Data were collected through medical chart abstractions and patient interviews. Comorbidities were abstracted from the chart by trained data personnel. All participating sites obtained Institutional Review Board protocol approval. As INTERMACS is considered a quality improvement registry and all patient identifiers were removed, the Institutional Review Board at the University of Alabama at Birmingham granted a waiver of individual patient informed consent for these analyses.
Quality of Life Data
Although INTERMACS began collecting data on patients with mechanical circulatory support in 2005, quality of life measures were not routinely collected until May 2012 (version 3.0). Assessment of quality of life is attempted on all patients at baseline and at 3 and 6 months after LVAD implantation and every 6 months thereafter for the life of the device (ie, INTERMACS stops quality-oflife data collection at the time of transplant or LVAD explant). 8 Disease-specific quality of life was assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), 9 a 23-item, self-administered questionnaire that assesses specific health domains pertaining to heart failure. 10 A 12-item version of the KCCQ was developed in 2013, 11 and INTERMACS began collecting this shortened version in 2014 (version 4.0). 8 Both versions yield an overall summary scale (KCCQ-OS), which was the primary quality-of-life outcome for our study and has a concordance of >0.98 between the 2 versions. Values for the KCCQ-OS range from 0 to 100, with higher scores indicating fewer symptoms, better function, and higher quality of life. Previous studies have suggested that KCCQ-OS scores correlate roughly with New York Heart Association Functional Class as follows: class I≈KCCQ-OS 75 to 100; class II≈60 to 74; class III≈45 to 59; and Class IV≈0-44. 12 The KCCQ has undergone extensive reliability and validity testing in various heart failure populations 9,13,14 and has been used in studies examining the changes in quality of life with LVADs.
15-17
Definition of Poor Outcome
We have previously examined several potential definitions for poor outcome that combine mortality and quality of life in a population of patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve replacement. 18 Similar to patients considering LVAD, patients with severe symptomatic aortic stenosis are expected to have limited life expectancy and poor quality of life without intervention. 1, 19 Moreover, both LVAD and transcatheter aortic valve replacement have substantial effects on both survival and quality of life in the majority of patients, 15, 16, 19 and yet both procedures have high residual morbidity and mortality despite intervention. 1, 19 For the purposes of this study, we used outcomes at 1 year after LVAD as the basis for our primary end point, as we reasoned that survival for at least 1 year with a reasonable quality of life would be the minimum acceptable outcome for patients considering LVAD.
We used heart failure-specific health status to define poor quality of life after LVAD because heart failure symptoms are a primary indication for LVAD and are therefore expected to be corrected, to a variable extent, in highly symptomatic patients. Although overall health status would also be expected to improve among highly symptomatic patients undergoing LVADs, generic health status measures are less sensitive to change and do not specifically assess symptoms and functional status along the disease pathway of heart failure. As such, they would not be as sensitive or specific as a disease-specific measure for determining whether a patient has had an acceptable outcome after LVAD. Therefore, poor outcome was defined as death or an average KCCQ-OS <45 throughout the year after implantation. 18, 20 We integrated quality of life during the follow-up time to avoid inadvertently labeling patients as having poor outcome because of temporary dips in quality of life at a single point in time. These outcomes were considered hierarchically-with death as the primary outcome and, if alive, then quality of life was examined. As such, there was no overlap between the outcomes (ie, quality of life was not considered as an outcome in patients before death, which may have increased the proportion of patients with poor quality-of-life outcomes after LVAD implantation).
Statistical Analysis
To reduce the effect of selection bias because of missing follow-up KCCQ data, we constructed a multivariable logistic regression model among patients who survived 1 year to determine the probability of having missing follow-up KCCQ data. We then weighted each of the surviving patients in the analytic cohort by the inverse probability of the likelihood of having missing data. 21 In this way, our analyses better reflected the overall LVAD population by giving more weight to the model for patients who were most like those who survived but did not complete follow-up KCCQ questionnaires. All analyses used these weighted estimates.
For the quality-of-life component of the outcome, we constructed a piecewise linear mixed-effects model to predict KCCQ scores at each follow-up assessment through survival or 1 year after LVAD implantation. The model included baseline patient characteristics, fixed and random effects for month, whether the patient died, and time to death. For each patient, poor quality of life was then defined as average area under the curve of <45, suggestive of persistent NYHA Class IV symptoms, on average, during the year after LVAD implantation, based on the patient's predicted KCCQ scores. This approach avoids overweighting declines in quality of life that are only transient in nature.
After defining the outcomes, the demographic and clinical characteristics were compared between patients who had a poor outcome and patients who had an acceptable outcome after LVAD implantation using t tests for continuous variables and χ 2 tests for categorical variables. All statistical analyses were performed with SAS, version 9.4 (SAS Institute, Inc, Cary, NC) and R version 3.2.0.
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Results
Patient Population
From May 2012 through September 2013, 3922 adult patients received durable LVADs and were enrolled in the INTERMACS registry. We excluded patients who received biventricular devices (n=31) and patients with device strategies of bridge to transplant (n=2208) or bridge to recovery, rescue therapy, or other indications (n=45; Figure) . As such, our analytic cohort included 1638 patients who received LVADs for destination therapy. The most common age group was 60 to 69 years of age, 19% were women, and 42% were INTERMACS profile 1 to 2 at implantation. Followup KCCQ data were missing on 16% of surviving patients. There were few clinical differences between those with and without follow-up KCCQ data ( Table I in the Data Supplement) . Notably, patients with missing follow-up data were more likely to have missing baseline KCCQ data (missing versus not missing follow-up data: 53% versus 38% missing baseline data; P<0.001), mostly for administrative reasons (eg, patient was not deemed too sick to complete the KCCQ; Table I in the Data Supplement).
Frequency of and Factors Associated With Poor Outcome
Among the 1638 patients with LVADs, 29.7% had poor outcome at 1 year after device implantation. This was because of death in 22.4% of patients and persistently poor quality of life in 7.3% of surviving patients. Among patients who died in the first year after LVAD, 70.6% died within the first 6 months, 23.4% died between 6 and 12 months and had a reasonable quality of life before death, and 6.0% died between 6 and 12 months with poor quality of life.
Compared with patients who survived 1 year with an acceptable quality of life after LVAD, those with poor outcomes were more likely to have higher body mass indices (29. 3 
Discussion
In a large, national registry of patients who received LVADs, we found that nearly one third of patients have a poor outcome during the year after device implantation. This was primarily driven by death, although 1 in 13 surviving patients had persistently poor quality of life throughout the year after treatment. We identified a few factors that were more common in patients who had a poor outcome, including previous cardiac surgery, anemia, obesity, and poorer heart failure symptoms and functional status at baseline. These data may be useful to calibrate patients' expectations of recovery after LVAD for destination therapy.
Importantly, this was a study examining patients who are not candidates for heart transplantation, and the factors that make these patients ineligible for transplantation are most commonly advanced age or comorbidities. Cardiac and noncardiac comorbidities, other than obesity and a history of cancer, were not as strongly associated with poor outcome, highlighting that the reasons that a patient may be ineligible for heart transplantation do not necessarily place the patient at high risk for poor outcome after LVAD. In addition, indices of right heart failure (eg, tricuspid regurgitation, pulmonary systolic pressure), which are often considered high-risk features for LVAD implantation, were not associated with a poor outcome after LVAD. However, it is important to note that all patients in our study received an LVAD, and thus the highestrisk patients, based on these factors, may have been appropriately treated with alternative strategies (eg, biventricular VAD and medical therapy) and were not included.
Previous Studies
Importantly, previous studies have focused on factors associated with mortality in isolation. Lower hematocrit was a significant predictor in the destination therapy risk score. 23 However, this was the only factor that overlapped with our data. Worse quality of life before LVAD implantation, as assessed with the KCCQ, has been shown not to be associated with mortality in 2 studies and is likely associated with poor outcome primarily because of its strong association with subsequent quality of life. 4, 24 By broadening our definition of poor outcome to include both poor quality of life and death, we think we have better encompassed the treatment goals of patients considering LVAD for destination therapy and, in the process, identified some novel factors associated with poor outcomes after LVAD. INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire-overall summary score; LVAD, left ventricular assist device; and NYHA, New York Heart Association.
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Challenges in Defining Poor Outcome
We think that our definition of poor outcome reflects a failure of the device to help some patients achieve its anticipated benefits. One could argue for different KCCQ score thresholds for poor quality of life, different follow-up time frames, or inclusion of additional end point components (eg, cognitive decline and stroke). Furthermore, there is almost certainly variability in how individual patients weigh the importance of death and quality of life in its regard to being a poor outcome after LVAD. Nevertheless, we think that this is an important initial step in defining how best to communicate the benefits of LVAD therapy to individual patients considering this treatment option. Importantly, by embracing a composite definition of poor outcome-however definedproviders can more consistently and accurately engage patients in shared medical decision making around LVAD therapy. This is important because it is well documented that the majority of educational materials explain potential LVAD treatment in ways that may not be correct for individual patients. 25 As a result, a recent study found that most patients expect greater improvements in their quality of life than they often experience. 26 There is a pressing need to improve communication with patients before LVAD implantation and to provide more realistic estimates of recovery. The use of an outcome that incorporates both survival and quality of life is likely to be an efficient means for communicating to patients the information they most value in making a decision, particularly because the KCCQ integrates numerous health status characteristics that patients care about, including heart failure symptoms, functional limitations, social limitations, and quality of life. This integration of quality of life outcomes may become even more relevant as LVADs begin to be tested and used in lower risk/less sick patients, who may have similar absolute survival with medical therapy.
Challenges in Predicting a Poor Outcome
Our original goal was to build a model of poor outcome that could be used before treatment to help guide patient selection and calibrate patients' and providers' expectations of recovery. However, we found this challenging to accomplish. First, one of the factors that was most strongly associated with poor outcomes was pre-LVAD quality of life. Unfortunately, because of the acute illness of patients before LVAD implantation in combination with administrative concerns of collecting pre-LVAD data for the registry, baseline quality of life has been challenging to collect in the sickest patients (eg, INTERMACS Profile 1). Although we could use techniques of imputation and various assumptions and sensitivity analyses, these would be inherently limited in truly understanding the baseline quality of life of patients with missing data. Second, the frequent occurrence of post-LVAD complications, such as stroke and bleeding, affect outcomes of both survival and quality of life and are, unfortunately, relatively unpredictable based on patient characteristics before LVAD. As technology and treatments improve, it is expected that these complications will decrease, increasing our ability to predict poor outcome based solely on baseline characteristics. Hopefully in the future, we will be able to construct valid models to estimate a patient's risk of poor outcome based on his or her individual characteristics and use this estimate to support decision making before this life-changing operation, particularly in patients with higher INTERMACS profiles where there is more discretion in using LVADs.
Limitations
Our findings should be interpreted in the context of several potential limitations. First, there are many aspects of quality of life that may be affected by the LVAD that are not captured by the KCCQ (eg, challenges with device management, stroke, frequent bleeding). Although a KCCQ-OS score <45 reflects a poor quality of life for patients with heart failure, it is likely that there are patients who report KCCQ-OS scores ≥45 but who have a poor quality of life for reasons not related to their heart failure. As such, it is likely that we have underestimated the proportion of patients who have poor quality of life after LVAD. Conversely, although most patients strongly value quality of life, 4 some patients may consider survival with a poor quality of life an acceptable outcome. In contrast, others may think that having persistent heart failure symptoms that are moderately limiting (ie, KCCQ-OS 45-60) represents a poor outcome. For these reasons, we may be over-or underestimating the percentage of patients with poor outcome because of poor quality of life. Second, follow-up KCCQ scores were missing on 15% of surviving patients. Although there were few meaningful differences between those with and without follow-up KCCQ data, we had to account for these differences by using inverse propensity weighting methods for all of our analyses.
Conclusions
Using a novel definition that integrates both survival and quality of life, we found that nearly one third of patients have poor outcome during the year after LVAD. Patients who had a poor outcome were more likely to have had previous cardiac surgery, anemia, obesity, and poorer functional status before LVAD implantation. Future efforts to build on these initial insights to develop risk models to support shared decision making, particularly in patients with higher INTERMACS profiles, should be considered, although these efforts may be challenging because of several factors, including unpredictable post-LVAD complications. Further research is needed to understand how best to communicate these risks to patients, so that the decision to proceed with LVAD treatment is concordant with patients' goals and values.
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